Related Experiment Video
Updated: Aug 15, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Engineering a synergistic antioxidant inhibition nanoplatform to enhance oxidative damage in tumor treatment
Qianqian Zhang1, Zhen Sun1, Wenbo Sun2
1State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, PR China; University of Science and Technology of China, Hefei 230026, PR China.
Abstract:
The antioxidant system of tumor cells severely impairs reactive oxygen species (ROS)-mediated tumor therapy. Despite extensive attempts to attenuate the antioxidant capacity by eliminating ROS scavengers such as glutathione (GSH), nicotinamide adenine dinucleotide phosphate (NADPH) over-expressed in the tumor microenvironment can regenerate GSH from glutathione disulfide (GSSG), hence weakening ROS-induced oxidative damage. Therefore, engineering a nanoplatform capable of depleting both NADPH and GSH is extremely significant for improving ROS-mediated tumor treatment. Herein, a synergetic antioxidant inhibition strategy is proposed to attenuate intracellular antioxidant capacity for hypoxic tumor therapy. In this context, both porous Prussian blue nanoparticles (PPB NPs) and cisplatin prodrug [cis-Pt (IV)] in the nanoplatform can oxidize GSH to directly reduce GSH levels, while PPB NPs also enable NADPH depletion by peroxidase-mimicking to impair GSH regeneration. Furthermore, PPB NPs with catalase-mimicking activity catalyze H2O2 decomposition to alleviate tumor hypoxia, thus reducing the generation of GSH and boosting singlet oxygen (1O2) production by Chlorin e6 (Ce6) for enhancing oxidative damage. Experimental results prove that the nanoplatform, denoted as PPB-Ce6-Pt, can induce remarkable tumor cells apoptosis and ferroptosis. Importantly, a simple loading method and the use of Food Drug Administration (FDA)-approved materials make PPB-Ce6-Pt have great potential for practical applications. STATEMENT OF SIGNIFICANCE: The antioxidant system in tumor cells disables ROS-mediated tumor therapy. Besides, extensive attempts aim at depleting GSH without considering their regeneration. Therefore, we developed a synergetic strategy to attenuate intracellular antioxidant capacity for hypoxic tumor therapy. PPB-Ce6-Pt nanoplatform could not only directly reduce GSH levels but also deplete NADPH by peroxidase-mimicking to impair GSH regeneration. In addition, PPB-Ce6-Pt nanoplatform could catalyze H2O2 decomposition to alleviate tumor hypoxia, thus reducing the generation of GSH and boosting 1O2 production by Chlorin e6 (Ce6) for increasing oxidative damage. Then, intracellular ROS boost and redox dyshomeostasis induced remarkable tumor cells apoptosis and ferroptosis. Importantly, a simple loading method and the use of biosafety materials made the nanoplatform have great potential for practical applications.
Insights
This study introduces a novel nanoplatform, PPB-Ce6-Pt, designed to overcome tumor cell antioxidant defenses. It effectively depletes glutathione (GSH) and nicotinamide adenine dinucleotide phosphate (NADPH), enhancing reactive oxygen species (ROS)-mediated cancer therapy for improved tumor apoptosis and ferroptosis.
Area of Science:
- Biomedical Engineering and Nanotechnology
- Cancer Therapy and Drug Delivery
- Oxidative Stress and Redox Biology
Background:
- Tumor cells possess robust antioxidant systems, primarily involving glutathione (GSH) and nicotinamide adenine dinucleotide phosphate (NADPH), which counteract reactive oxygen species (ROS)-mediated therapies.
- Existing strategies to deplete GSH often fail due to NADPH-dependent regeneration, limiting the efficacy of ROS-based cancer treatments.
- Hypoxic tumor microenvironments further complicate treatment by influencing antioxidant levels and redox balance.
Purpose of the Study:
- To engineer a nanoplatform that simultaneously depletes both GSH and NADPH to overcome tumor cell antioxidant defenses.
- To enhance the efficacy of ROS-mediated tumor therapy, particularly in hypoxic conditions.
- To develop a potential therapeutic agent with broad applicability using safe, readily available materials.
Main Methods:
- Development of a nanoplatform (PPB-Ce6-Pt) integrating porous Prussian blue nanoparticles (PPB NPs) and a cisplatin prodrug [cis-Pt (IV)].
- PPB NPs were designed with peroxidase-mimicking activity for NADPH depletion and catalase-mimicking activity for H2O2 decomposition.
- The nanoplatform was evaluated for its ability to oxidize GSH, deplete NADPH, alleviate hypoxia, and induce oxidative damage via singlet oxygen (1O2) production.
Main Results:
- The PPB-Ce6-Pt nanoplatform effectively reduced intracellular GSH levels and inhibited NADPH-dependent GSH regeneration.
- Catalase-mimicking activity of PPB NPs alleviated tumor hypoxia, promoting singlet oxygen (1O2) generation by Chlorin e6 (Ce6).
- The nanoplatform induced significant tumor cell apoptosis and ferroptosis, demonstrating enhanced oxidative damage and redox dyshomeostasis.
Conclusions:
- The developed PPB-Ce6-Pt nanoplatform offers a synergistic strategy to attenuate intracellular antioxidant capacity for improved hypoxic tumor therapy.
- This approach effectively overcomes tumor antioxidant defenses by targeting both GSH and NADPH, leading to enhanced ROS-mediated cell death.
- The use of FDA-approved materials and a simple loading method positions PPB-Ce6-Pt as a promising candidate for clinical translation in cancer treatment.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...